Novartis Investigative Site

Ioannina, GR 455 00

0 studies enrolling now · 9 studies all time

What they study most

Behcet Disease, Breast Cancer, Diffuse Large B-cell Lymphoma, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction (HF-rEF), Myelodysplastic Syndromes, Tuberous Sclerosis Complex-associated Refractory Seizures, Uveitis, cMET-dysregulated Advanced Solid Tumors

Studies at this site

• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
• A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors — Completed
• Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures — Completed
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy — Completed
• 38 Week Extension Study to CAIN457C2303 — Stopped early
• Phase III Study in Refractory Behcet's Disease — Completed